Could retatrutide help people whose weight loss has stalled on semaglutide or tirzepatide?
Medscape looks at whether retatrutide's added glucagon action could help patients who plateau on current GLP-1 jabs, after phase 3 data showed 28.3% average loss at the top dose. Experts caution the mechanism is promising but unproven as a switching strategy, and retatrutide remains an unapproved, investigational drug.
Source: Medscape (20 Oct 2026).